Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Technology > Marketing Technology

Nestle to develop Alzheimer’s test in Swiss research alliance

Your article was successfully shared with the contacts you provided.

(Bloomberg) — Nestle SA, the world’s largest food company, formed a research alliance with a Swiss drug developer to work on a test that could diagnose Alzheimer’s disease in its early stages.

AC Immune SA, based in Lausanne, will provide expertise to develop a diagnostic test, according to a statement released Wednesday. It’s based on an antibody technology that originated at Prometheus Laboratories Inc., which Nestle acquired in 2011.

Nestle has been building a business that would treat chronic disease through nutrition as the food company seeks new growth markets after cornering leading positions in categories such as bottled water, pet-food and soluble coffee. There are 9.9 million new cases of Alzheimer’s each year, and the cost of dementia has increased to $818 billion from $604 billion in 2010, AC Immune said.

“Early diagnosis is critical,” Ed Baetge, head of the Nestle Institute of Health Sciences, said in the statement. “Our overarching goal is to develop nutritional approaches and technologies that help people maintain or reestablish their cognitive vigor.”

See also: LTC medicine chest: Top 10 supplements


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.